SG11202112117TA - Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke - Google Patents

Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke

Info

Publication number
SG11202112117TA
SG11202112117TA SG11202112117TA SG11202112117TA SG11202112117TA SG 11202112117T A SG11202112117T A SG 11202112117TA SG 11202112117T A SG11202112117T A SG 11202112117TA SG 11202112117T A SG11202112117T A SG 11202112117TA SG 11202112117T A SG11202112117T A SG 11202112117TA
Authority
SG
Singapore
Prior art keywords
haptoglobin
treating
outcome following
neurological outcome
haemorrhagic stroke
Prior art date
Application number
SG11202112117TA
Inventor
Michael Hugelshofer
Christian Schaer
Dominik Schaer
Original Assignee
Univ Zuerich
Csl Behring Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich, Csl Behring Ag filed Critical Univ Zuerich
Publication of SG11202112117TA publication Critical patent/SG11202112117TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202112117TA 2019-05-17 2020-05-15 Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke SG11202112117TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962849249P 2019-05-17 2019-05-17
US201962878062P 2019-07-24 2019-07-24
PCT/EP2020/063732 WO2020234195A1 (en) 2019-05-17 2020-05-15 Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke

Publications (1)

Publication Number Publication Date
SG11202112117TA true SG11202112117TA (en) 2021-12-30

Family

ID=70779726

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112117TA SG11202112117TA (en) 2019-05-17 2020-05-15 Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke

Country Status (12)

Country Link
US (1) US20220211808A1 (en)
EP (1) EP3968988A1 (en)
JP (1) JP2022533365A (en)
KR (1) KR20220009984A (en)
CN (1) CN114007639A (en)
AU (1) AU2020277640A1 (en)
BR (1) BR112021022940A2 (en)
CA (1) CA3138650A1 (en)
CL (1) CL2021003033A1 (en)
IL (1) IL287864A (en)
SG (1) SG11202112117TA (en)
WO (1) WO2020234195A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230142569A (en) * 2021-02-01 2023-10-11 체에스엘 베링 아게 Methods for Treating or Preventing Secondary Neurological Adverse Events After Hemorrhagic Stroke

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061735A (en) 1973-11-15 1977-12-06 The Green Cross Corporation Haptoglobin in aqueous solution and process for preparing the same
US4137307A (en) 1973-11-15 1979-01-30 The Green Cross Corporation Process for preparing haptoglobin aqueous solution using strong anion exchanger
JPS52128205A (en) * 1976-04-16 1977-10-27 Green Cross Corp:The Prophylactic and therapeutic drugs for cerebro-vascular contraction
WO1996018412A1 (en) 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
SI2298347T1 (en) 2003-05-06 2016-03-31 Biogen Hemophilia Inc. Clotting factor chimeric proteins for treatment of a hemostatic disorder
BRPI0411132B8 (en) 2003-06-12 2021-05-25 Lilly Co Eli heterologous fusion protein and its uses
PT1699821E (en) 2003-12-31 2012-08-23 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US20060057065A1 (en) 2004-09-11 2006-03-16 Yanming Wang Composition and method to prevent and treat brain and spinal cord injuries
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US20080293623A1 (en) * 2007-04-30 2008-11-27 Nhs Blood And Transplant Enriched haptoglobin polymers for the treatment of disease
PL2814502T3 (en) 2012-02-15 2018-02-28 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
US9534029B2 (en) 2012-10-03 2017-01-03 Csl Behring Ag Method of purifying proteins
SG11201501921SA (en) 2012-10-03 2015-04-29 Csl Behring Llc A method of purifying proteins

Also Published As

Publication number Publication date
BR112021022940A2 (en) 2022-01-18
JP2022533365A (en) 2022-07-22
KR20220009984A (en) 2022-01-25
CL2021003033A1 (en) 2022-09-20
EP3968988A1 (en) 2022-03-23
AU2020277640A1 (en) 2022-01-20
IL287864A (en) 2022-01-01
CN114007639A (en) 2022-02-01
US20220211808A1 (en) 2022-07-07
WO2020234195A1 (en) 2020-11-26
CA3138650A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
IL277333A (en) Methods for treating ocular diseases
EP3963390C0 (en) Diffractive backlight fabrication method
IL287864A (en) Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke
IL310975A (en) Lou064 for treating multiple sclerosis
IL283443A (en) Vdac inhibitors for treating autoimmune diseases
EP3752247A4 (en) Immune dose computation for treatment plan optimization in radiotherapy
EP4069087A4 (en) Cover for a radiotherapy device
SG10201912696XA (en) Dynamically-Generated Electronic Database for Portfolio Selection
IL289436A (en) Methods for treating ocular diseases
GB202019188D0 (en) Methods for adaptive radiotherapy
IL284629A (en) Methods for treating ocular surface pain
IL288797A (en) Treatment for synucleinopathies
SG11202110659SA (en) Method for treating ocular diseases
PL4080313T3 (en) Treatment system for treating workpieces
GB201910469D0 (en) Baffle for use with a treatment machine
SG11202106477SA (en) Inductive joystick
ZA202302018B (en) A prescription for treating the prostate
GB202117290D0 (en) Treat dispensing muzzle
GB202312184D0 (en) Treat dispensing muzzle
IL285603A (en) A kit for treating pelvic pain arising from female reproductive system
EP4058063A4 (en) Methods for treating diseases
IL292278A (en) Combination therapy for treating a hematological malignancy
GB201913294D0 (en) Neurological modification therapy
HUE058014T2 (en) Treatment system for treating workpieces
GB2586133B (en) Method for use with a Radiotherapy Device